Pulmonx Corporation (LUNG)
| Previous Close | 6.91 |
| Open | 6.78 |
| Bid | 6.35 x 100 |
| Ask | 6.42 x 100 |
| Day's Range | 6.27 - 7.88 |
| 52 Week Range | 5.67 - 14.84 |
| Volume | |
| Avg. Volume | 395,290 |
| Market Cap | 248.809M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.54 |
| Earnings Date | Oct 28, 2024 - Nov 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.50 |
ZacksPulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of 4.88% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswirePulmonx Reports Second Quarter 2024 Financial Results
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights Achieved record worldwide revenue of $20.8 million in the second quarter of 2024, a 21% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $13.9 million in U.S
- GlobeNewswire
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET. A live and archived webcast of the presentation will be available on the “Investors” section of the Pulmonx websit
